Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Despite widespread use of statins to reduce low-density lipoprotein cholesterol (LDL-C) and associated atherosclerotic cardiovascular risk, many patients do not achieve sufficient LDL-C lowering due to muscle-related side effects, indicating novel treatment strategies are required. Bempedoic acid (ETC-1002) is a small molecule intended to lower LDL-C in hypercholesterolemic patients, and has been previously shown to modulate both ATP-citrate lyase (ACL) and AMP-activated protein kinase (AMPK) activity in rodents. However, its mechanism for LDL-C lowering, efficacy in models of atherosclerosis and relevance in humans are unknown. Here we show that ETC-1002 is a prodrug that requires activation by very long-chain acyl-CoA synthetase-1 (ACSVL1) to modulate both targets, and that inhibition of ACL leads to LDL receptor upregulation, decreased LDL-C and attenuation of atherosclerosis, independently of AMPK. Furthermore, we demonstrate that the absence of ACSVL1 in skeletal muscle provides a mechanistic basis for ETC-1002 to potentially avoid the myotoxicity associated with statin therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 ETC-1002-CoA inhibits ACL and mediates β1-selective AMPK activation. Recombinant human ACL was incubated in the presence of the indicated concentrations of ETC-1002-CoA (a–c) or ETC-1002 (d), and (a) coenzyme A (CoA), (b) citrate or (c) ATP. Conversion of [14C]-citrate to [14C]-acetyl-CoA was measured in counts per minute (CPM). Recombinant human (e) AMPKα1β1γ1 and (f) AMPKα1β2γ1 complexes were incubated in the presence of the indicated concentrations of ETC-1002, ETC-1002-CoA, AMP or A-769622. (g) Structure of ETC-1002 and the biochemical reaction that generates ETC-1002-CoA acyl-CoA synthetase (ACS). ETC-1002-CoA/CoASH enzyme ACL kinetic analyses are single measures, and representative results from n=3 independent experiments shown; AMPK activity was determined by time-resolved fluorescence resonance energy transfer expressed as mean±s.e.m. of triplicate measures. (a) Ki calculated by Michaelis–Menten kinetic analysis.](https://figures.cochat.ai/paper-figures/02df10a0267b44eda297dc9dcee13726/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-1.jpg)
![Figure 2 Differentiation of ETC-1002 from the myotoxic effects of statins. [14C]-ETC-1002 (10 μM) conversion to [14C]-ETC-1002-CoA in human liver microsomes was determined in the presence of 30 μM unlabelled (a) monocarboxylic and (b) dicarboxylic saturated competitive fatty acid substrates. RH7777 cells were treated with negative control (Control) or Slc27a2 (ACSVL1) siRNA; n=6, for 48 h, and (c) ACSVL1 expression determined by western blot, and [14C]-ETC-1002-CoA synthesis determined; n=3. (d) Both control and Slc27a2 siRNA-treated RH7777 cells were treated with vehicle, ETC-1002 (30 μM) or atorvastatin (0.5 μM), and de novo cholesterol synthesis measured over 4 h; n=6 transfections. (e) Relative ACSVL1 expression in microsomes prepared from human liver, kidney and skeletal muscle (SkM). (f) ETC-1002-CoA synthetase activity in microsomes prepared from human liver and skeletal muscle; palmitate (10 μM) used as a positive control for skeletal muscle microsome viability. (g) ACSVL1 expression was measured in primary human hepatocytes and primary human skeletal muscle (SkM) cells by western blotting and expressed relative to β-actin. (h) Primary human myotubes were treated with vehicle (Veh.), simvastatin 10 μM (Simva), atorvastatin 10 μM (Atorva) or ETC-1002 100 μM in the presence of [14C]-glucose for 12 h, and incorporation into non-saponifiable lipids determined; or treated with 0.1–100 μM simvastatin, atorvastatin or ETC-1002 for 48 h and (i) cytotoxicity was measure by GF-AFC/bis-AAF-R110 cleavage, and (j) Caspase 3,7 activity (DEVD cleavage) determined. Data for myotube cytotoxicity assays are expressed as mean±s.e.m., n=2 performed in triplicate. Data for liver (n=50 donors pooled) and kidney (n=50 donors pooled) microsome preparations are representative of two independent experiments performed in duplicate, and expressed as mean±s.d. Data for human skeletal muscle microsomes (n=4 pooled donors) are the mean±s.e.m. of two independent experiments performed in triplicate. Multiple comparisons were made using an one-way ANOVA, Bonferroni's multiple comparisons test; *P<0.05.](https://figures.cochat.ai/paper-figures/aa53cfde988849fa938e4aa3379a9671/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-2.jpg)


![Figure 5 ACL suppression increases LDLR. (a) Primary human hepatocytes were treated with vehicle or ETC-1002 (100 μM) for 18 h in the presence of [3H]-H2O or pretreated with the indicated concentrations of ETC-1002 for 1 h, following a 3 h [14C]-acetate pulse. Counts incorporated into the non-saponifiable (sterols), and saponifiable (fatty acids) lipid fractions were determined and expressed as % vehicle. (b) Primary human hepatocytes were treated with vehicle, atorvastatin (0.5 μM) or ETC-1002 (100 μM) for 36 h and total intracellular cholesterol concentrations were determined in cell lysates. (c) Media was assayed for apoB by enzyme-linked immunosorbent assay. (d) PHHs were treated with ETC-1002 for the indicated time points and the apoB concentrations were measured in the media. (e) PHH were pre-labelled overnight with [14C]-oleate and the effects of ETC-1002 treatment on oleate-derived counts in the media determined at the indicated time points. PHH hepatocytes were treated with ETC-1002 and atorvastatin, and (f) mRNA levels for HMGR, SREBF2, PCSK9 and LDLR were determined by reverse transcription–quantitative PCR or (g) LDL receptor activity determined; A-769662 (10 μM). (h) RH7777 cells were treated with the indicated concentrations of ETC-1002 or atorvastatin (0.5 μM), and [14C]-lactate incorporation into cholesterol (Chol), cholesteryl esters (CE) and triglycerides determined. (i) LDLR-mediated DiI–LDL uptake in response to the indicated concentrations of ETC-1002±atorvastatin (0.5 μM). RH7777 cells were subjected to negative control (NC) or Acly siRNA-mediated gene silencing (n=3) and analysed for (j) ACL LDLR protein levels, or (k) LDLR-mediated DiI–LDL uptake. Data for PHH are expressed as mean±s.e.m. of n=2 donors performed in triplicate (a–c,f,g; except A-769662 treatment was 1 donor) or representative of two independent experiments showing similar results (d,e). (h) IC50 and (i) EC50 determinations were made using nonlinear curve fit model. Multiple comparisons were made using (a,j,k) unpaired Student's t-test or (b,c,f,g) an one-way ANOVA, Bonferroni's multiple comparisons test; *P<0.05.](https://figures.cochat.ai/paper-figures/bdd7bd8103b34bfd9b8c72b35fad6960/liver-specific-atp-citrate-lyase-inhibition-by-bempedoic-acid-decreases-ldl-c-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bempedoic acid is a pro-drug that reduces cholesterol synthesis by inhibiting adenosine triphosphate (ATP) citrate lyase, with very limited musculoskeletal-related side effects.280”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [280]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081 · cited 1×
“Triacsin C is a potent inhibitor of ACSL1 and 4, and a weak inhibitor of ACSVL1 (refs 43–47).”
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834 · cited 1×
“Upregulation of the LDL receptor results in a new homeostatic state, where more cellular cholesterol is derived from blood LDL particles, thus reducing blood LDL-C 51–53 .”
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Mihaylova, M. M., & Shaw, R. J. (2011) · Nature Cell Biology · doi:10.1038/ncb2329 · Cited by 2,923
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Cited by
Items 201–300 of 499
Effective prevention of atherosclerosis by non-viral delivery of CRISPR/Cas9
Chen, X., Zhang, X., Yang, W., Gao, S., Zhao, N., Li, Y., Du, J., Li, Y., & Xu, F. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102097 · Cited by 14
Mormone, A., Tortorella, G., Esposito, F., Caturano, A., Marrone, A., Cozzolino, D., Galiero, R., Marfella, R., Sasso, F. C., & Rinaldi, L. (2024) · Biomedicines · doi:10.3390/biomedicines12020432 · Cited by 19
“Blocking this enzyme increases LDL-R on the membrane, resulting in reduced circulating LDL, lipid reduction, decreased hepatic steatosis, and increased weight loss [65,66].”
BackgroundStrategies for chronic coronary disease: A brief guide for clinicians
Krittanawong, C., Khawaja, M., Virk, H. U. H., Escobar, J., Khalid, U., Birnbaum, Y., Lavie, C. J., Sharma, S. K., Jneid, H. M., Rao, S. V., et al. (2024) · npj Cardiovascular Health · doi:10.1038/s44325-024-00006-w · Cited by 21
Bhattacharyya, U., Pooventhiran, T., & Thomas, R. (2021) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2021.119630 · Cited by 13
Curcumin nicotinate decreases serum LDL cholesterol through LDL receptor-mediated mechanism
Zhang, C., Xiang, D., Zhao, Q., Jiang, S., Wang, C., Hui-xian, Y., Huang, Y., Yuan, Y., Liu, X., Huang, Z., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175195 · Cited by 16
Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance
Susekov, A. V., Король, Л. А., & Watts, G. F. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07139-x · Cited by 13
“Another unique feature of ETC-1002 is “muscle friendly”metabolism, since bempedoic acid does not suppress the synthesis of cholesterol or other biological intermediates required for normal muscle function [14].”
BackgroundInfluentialBempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties.
Marín, L. M., & Gil, N. P. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.012 · Cited by 24
Statin intolerance: myths and facts
Laufs, U., & Isermann, B. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa582 · Cited by 14
Sun, Q., Guo, Y., Hu, W., Zhang, M., Wang, S., Lei, Y., Meng, H., Li, N., Xu, P., Li, Z., et al. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001449 · Cited by 14
“BA is clinically employed for the management of dyslipidemia by suppressing lipid biosynthesis dependent on ACLY (Pinkosky et al., 2016; Banach et al., 2020).”
BackgroundComprehensive review of statin-intolerance and the practical application of Bempedoic Acid
Yarrarapu, S. N. S., Goyal, A., Venkata, V. S., Panchal, V. S., Sivasubramanian, B. P., Du, D. T., Jakulla, R. S., Pamulapati, H., Afaq, M. A., Owens, S., et al. (2024) · Journal of Cardiology · doi:10.1016/j.jjcc.2024.03.006 · Cited by 15
Butera, E., Termite, F., Esposto, G., Galasso, L., Mignini, I., Borriello, R., Ainora, M. E., Miele, L., Gasbarrini, A., & Zocco, M. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136938 · Cited by 15
Averna, M. R., & Catapano, A. L. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.10.017 · Cited by 14
How I Treat statin-associated Side Effects in an Outpatient Setting
Pulipati, V. P., & Davidson, M. H. (2021) · Future Cardiology · doi:10.2217/fca-2020-0153 · Cited by 14
HDL metabolism and function in diabetes mellitus
Cochran, B. J., King, T. W., Chemello, K., Thomas, S. R., & Rye, K. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01176-y · Cited by 18
Xu, Q., Cheng, A., Li, B., Tian, X., Han, Z., & Feng, Z. (2024) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12427 · Cited by 14
“To date, BA is the only drug that targets ACLY and has been approved by the FDA that was designed as a lipid-lowering medication, but its effect in tumour treatment remains unclear (Nissen et al., 2023; Pinkosky et al., 2016).”
BackgroundPuertas-Umbert, L., Alonso, J., Blanco-Casoliva, L., Almendra‐Pegueros, R., Camacho, M., Rodríguez‐Sinovas, A., Galán, M., Roglans, N., Laguna, J. C., Martínez‐González, J., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117876 · Cited by 12
Activating AMPK improves pathological phenotypes due to mtDNA depletion
Carvalho, G., Nguyen, T., Repolês, B. M., Forslund, J. M. E., Wijethunga, W. M. R. R., Ranjbarian, F., Mendes, I. C., Gorospe, C. M., Chaudhari, N., Falabella, M., et al. (2025) · FEBS Journal · doi:10.1111/febs.70006 · Cited by 13
Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents
Stoll, F., Eidam, A., Michael, L., Bauer, J. M., & Haefeli, W. E. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00928-z · Cited by 14
Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms
Kallapur, A. S., & Sallam, T. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.12.011 · Cited by 14
Chan, Y., & Ramji, D. P. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_2 · Cited by 15
Allosteric role of the citrate synthase homology domain of ATP citrate lyase
Wei, X., Schultz, K. C., Pepper, H. L., Megill, E., Vogt, A. D., Snyder, N. W., & Marmorstein, R. (2023) · Nature Communications · doi:10.1038/s41467-023-37986-9 · Cited by 12
Biju, A. K., Lakshmikumar, R. R. C., & Rengasamy, K. R. R. (2024) · Natural Resources for Human Health · doi:10.53365/nrfhh/189500 · Cited by 11
Zhao, S., Guo, H., Qiu, L., Zhong, C., Xue, J., Qin, M., Zhang, Y., Xu, C., Xie, Y., & Yu, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-61209-w · Cited by 16
“LDL, primarily responsible for cholesterol transportation to peripheral arterial walls during the fasting plasma state, plays a crucial role in promoting atherosclerosis by facilitating the entry and oxidation of small LDL particles 23 .”
BackgroundLipids and Inflammation: Novel Molecular Targets and Therapeutic Implications
Triglia, L. T., Gurgoglione, F. L., Barocelli, F., Bianconcini, M., & Niccoli, G. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673311105240902053715 · Cited by 12
Yamashita, S., Kiyosue, A., Fujita, H., Yokota, D., Nakamura, Y., & Yasuda, S. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0089 · Cited by 16
Agha, A. M., Jones, P. H., Ballantyne, C. M., Virani, S. S., & Nambi, V. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.07.002 · Cited by 13
Goldberg, A. C., Banach, M., Catapano, A. L., Duell, P. B., Leiter, L. A., Hanselman, J. C., Lei, L., & Mancini, G. B. J. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117192 · Cited by 15
“Bempedoic acid is a prodrug activated in the liver by very long-chain acyl-CoA synthetase-1 (ACSVL1), leading to the reduction of cholesterol synthesis and upregulation of hepatic low-density lipoprotein (LDL) receptors that mediate increased uptake and clearance of plasma LDL [15].”
BackgroundInfluentialNovel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 14
Bempedoic acid directly binds and activates PPARα
Papa, C., Rose, A., Martin, H., Useini, A., Florian, G., Liao, L., Rodríguez‐Aguilera, J. R., Allo, P. V., Hoffmann, A., Tvardovskiy, A., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2025.12.018 · Cited by 10
Personalized Medicine in Lipid-Modifying Therapy
Tomlinson, B., Lin, C.-H., Chan, P., & Lam, C. W. K. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0110 · Cited by 12
Amore, B. M., Patel, N. K., Batheja, P., Templeton, I. E., Jones, H. M., Louie, M. J., & Emery, M. G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051476 · Cited by 13
“The pharmacologically active ETC-1002-CoA inhibits ATP citrate lyase, a precursor to 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase in the pathway of cholesterol biosynthesis, and subsequently leads to LDL receptor upregulation and decreases in LDL-C levels [2].”
BackgroundWright, J., & Subramanian, S. (2024) · The Medical clinics of North America · doi:10.1016/j.mcna.2024.03.005 · Cited by 9
Sun, J., Liu, J., Chen, F., Wang, X., & Wu, G. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2445774 · Cited by 16
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action
Roglans, N., Laguna, J. C., & Alegret, M. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000878 · Cited by 11
Bempedoic Acid and the Prevention of Cardiovascular Disease
Keaney, J. F. (2023) · New England Journal of Medicine · doi:10.1056/nejme2300793 · Cited by 11
ACLY and CKD: A Mendelian Randomization Analysis
Mohammadi‐Shemirani, P., Chong, M., Perrot, N., Pigeyre, M., Steinberg, G. R., Paré, G., Krepinsky, J. C., & Lanktree, M. B. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.04.013 · Cited by 9
Self-citationLaufs, U., Lincoff, A. M., Nicholls, S. J., Li, N., Bloedon, L. T., Sasiela, W. J., Powell, H. A., Herout, P. M., Thompson, P. D., & Nissen, S. E. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.014 · Cited by 12
Reshaping Dyslipidaemia Treatment with Bempedoic Acid—A Narrative Review
Strikić, D., Begic, Z., Radman, I. B., Zlopasa, F., Mateljic, J., Zec, I., Titlić, M., Slišković, A. M., Pećin, I., Reiner, Ž., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13061460 · Cited by 12
“In contrast, in the CLEAR Outcomes study, the rates of treatment discontinuation were similar in the two groups—11.3% in the bempedoic acid group and 11.2% in the placebogroup— indicating no significant difference [19,35,42].”
InfluentialTomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
Venkatraman, S., Das, S., Eerike, M., Cherian, J. J., & Bagepally, B. S. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03555-8 · Cited by 11
Asbeutah, A. A., Asbeutah, S. A., & Abu-Assi, M. A. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.06.058 · Cited by 10
Karla, V. R., Mucherla, R., & Chitta, R. K. (2022) · Chemistry Africa · doi:10.1007/s42250-022-00392-7 · Cited by 11
“The very-long-chain acyl-CoA synthetase-1 (ACSVL-1) enzyme, expressed in the liver, but not functional in the skeletal muscle, converts BPA (ETC-1002) to the active form (ETC-1002-CoA) [7].”
BackgroundCurrent and future options in cholesterol lowering treatments
Elis, A. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.02.010 · Cited by 12
Nissen, S. E. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.019 · Cited by 10
“Bempedoic acid is an LDL-lowering drug treatment that works by inhibition of adenosine triphosphate-citrate lyase (ACL), an enzyme upstream of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway (6).”
BackgroundSrivastava, R. A. K. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.08.010 · Cited by 8
Monocytic microRNAs—Novel targets in atherosclerosis therapy
Euler, G., & Parahuleva, M. S. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16367 · Cited by 10
“Bempedoic acid is another nonstatin, an ATP citrate lyase inhibitor that targets cholesterol synthesis upstream of HMG-CoA-reduc-tase, the enzyme inhibited by statins, which reduce LDL-C levels in the circulation (Pinkosky et al., 2016).”
Evolution of LDL-C lowering medications and their cardiovascular benefits: Past, present, and future
Faluk, M. A., Wardhere, A., Mohamoud, A. A., Nor, M. A., Bampastsias, D., Oikonomou, E., Almubaid, Z., & Hemyari, B. A. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102637 · Cited by 9
Pezzoli, A., Abenavoli, L., Scarcella, M., Rasetti, C., Svegliati‐Baroni, G., Tack, J. F., & Scarpellini, E. (2025) · Medicina · doi:10.3390/medicina61030387 · Cited by 11
“…hepatic generation of cholesterol, upregulates the LDL receptor expression within the liver, and clears the circulating LDL-C from the systemic circulation [96] [Figure 3]. the LDL receptor expression within the liver, and clears the circulating LDL-C from the systemic circulation [96] [Figure 3].”
Russo, V., Ratti, G., Parrella, A., De Falco, A., Crisci, M., Franco, R., Covetti, G., Caturano, A., Napolitano, G., Scotto di Uccio, F., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061839 · Cited by 8
Zang, Y.-J., Shi, M., Tai, L., Hu, Y.-Y., Wang, Y., Zheng, R., Feng, Z., Yuan, H., Wen, X., & Dai, L. X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117684 · Cited by 8
Uddin, N., Syed, A. A., Ismail, S. M., Ashraf, M. T., Khan, M. K., & Sohail, A. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102003 · Cited by 8
Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia
Averna, M. R., Bilato, C., & Sesti, G. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.023 · Cited by 8
Seijas‐Amigo, J., Cordero, A., Olmo, R. F., Quiroga, G. A. C., Fácila, L., Salgado‐Barreira, Á., Reyes-Santías, F., Romero‐Menor, C., Rondán, J., Rodríguez‐Mañero, M., et al. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001365 · Cited by 8
Jadhav, S. B., Amore, B. M., Bockbrader, H. N., Crass, R. L., Chapel, S. H., Sasiela, W. J., & Emery, M. G. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09864-w · Cited by 9
Wittlinger, T., Schwaab, B., Völler, H., Bongarth, C., Heinze, V., Eckrich, K., Guha, M., Richter, M., & Schlitt, A. (2021) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd8090105 · Cited by 9
Interindividual variability in statin pharmacokinetics and effects of drug transporters
Hirota, T., & Ieiri, I. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2305746 · Cited by 10
“Bempedoic acid is a prodrug and requires activation by the enzyme very-long-chain acyl-CoA synthetase [27].”
BackgroundAmore, B., Macdougall, D., Hanselman, J., & Emery, M. (2023) · Clinical pharmacology in drug development · doi:10.1002/cpdd.1297 · Cited by 5
Abrahams, T., & Nicholls, S. J. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2292039 · Cited by 8
“ACL is an enzyme that plays a crucial role in de novo hepatic lipid synthesis, converting citrate to acetyl-CoA and oxaloacetate [30].”
BackgroundStatin alternatives for the treatment of hypercholesterolemia - a safety evaluation
Zeng, W., & Tomlinson, B. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2424411 · Cited by 8
“It is not expected to cause skeletal muscle problems that may occur with statins as it is activated selectively in the liver [52].”
Bentanachs, R., Velázquez, A. M., Sánchez, R. M., Alegret, M., Laguna, J. C., & Roglans, N. (2022) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2022.03.001 · Cited by 7
Mohan, G. V. K., Chenna, V. S. H., Tirumandyam, G., Mian, A. R., Rashid, A., & Saleem, F. (2023) · Cureus · doi:10.7759/cureus.38662 · Cited by 11
“This enzyme is located upstream of β-hydroxy β-methylglutaryl-coenzyme A, which is also targeted by statins [8].”
BackgroundAtherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies
Omari, M., & Alkhalil, M. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11040126 · Cited by 11
“It is an oral prodrug, and its metabolites target ATP-citrate lyase (ACL), an enzyme that is upstream from HMG coenzyme A reductase, the enzyme inhibited by statins [38].”
BackgroundNovel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 8
Recent insights into low-density lipoprotein metabolism and therapy
Pirillo, A., Catapano, A. L., & Norata, G. D. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000727 · Cited by 7
“acid was shown to efficiently inhibit ACLY in the liver [6].”
BackgroundBempedoic acid: Review of a novel therapy in lipid management
Delevry, D., & Gupta, E. K. (2021) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa352 · Cited by 8
Yamashita, S., Fujita, H., Yokota, D., Isogai, Y., & Kitamoto, R. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65336 · Cited by 6
Yang, Y., Yi, X., Liu, C., Zeng, Q., Li, X., Luo, H., Yan, P., Gu, S., Li, C., Xiao, L.-H., et al. (2025) · Medical Microbiology and Immunology · doi:10.1007/s00430-025-00836-0 · Cited by 7
“In our model, short-term inhibitor administration caused no acute toxicity; however, chronic suppression risks metabolic derange - ments (e.g., dyslipidemia) or compromised tissue repair, as reported elsewhere [35].”
Li, D., Liu, Z., & Jiang, H. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02862-0 · Cited by 10
“Notably, its active metabolite is generated selectively within hepatocytes, which markedly limits systemic exposure and translates into a low risk of muscle-related adverse events [106].”
Role of bempedoic acid in patients with hypercholesterolemia and statin intolerance
Girardi, J. M., & do Couto, A. A. (2023) · Journal Archives of Health · doi:10.46919/archv4n1-011 · Cited by 7
Bempedoic acid for the treatment of hypercholesterolemia
Yang, J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1782744 · Cited by 6
“ACL is a key metabolic enzyme located in upstream of HMG-CoA reductase, it links the degradation of glucose to the synthesis of fatty acids and cholesterol [24,25].”
BackgroundPatti, G., Cavallari, I., Cesaro, A., Gragnano, F., Riva, L., Fimiani, F., Cuccia, C., Fresco, C., Calabrò, P., Leonardi, S., et al. (2022) · Vascular Pharmacology · doi:10.1016/j.vph.2022.107137 · Cited by 6
Alunno, A., Carubbi, F., Campanozzi, E., Bellisario, F., Schoones, J. W., Mariani, F. M., Ruscio, E. D., Altieri, P., & Ferri, C. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1234601 · Cited by 6
Wang, K., Li, Z., Zhang, W., Liu, Y., Wang, X., Sun, M., Fang, X., & Han, W. (2024) · Fitoterapia · doi:10.1016/j.fitote.2024.105964 · Cited by 6
Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment
Sugiyama, K., & Saisho, Y. (2018) · Diseases · doi:10.3390/diseases6020044 · Cited by 7
“Bempedoic acid (ETC-1002) is a once-daily, orally administered prodrug that inhibits adenosine triphosphate citrate lyase (ACL), a key enzyme upstream of HMGCR involved in the synthesis of fatty acids and cholesterol [54,55].”
BackgroundNovel and Emerging Therapeutics for Primary Prevention of Cardiovascular Disease
Buckley, L. F., Carbone, S., Aldemerdash, A. M., Fatani, N., & Fanikos, J. R. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.08.019 · Cited by 7
Bentanachs, R., Velázquez, A. M., Sánchez, R. M., Alegret, M., Laguna, J. C., & Roglans, N. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.09.004 · Cited by 8
Lipids | Cholesterol Synthesis and Regulation
Shao, W., & Espenshade, P. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00021-9 · Cited by 7
Ahmed, A. A., Mohamed, S. K., Nofal, S., Morsy, E. M. E., & Ahmed, A. A. E. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121963 · Cited by 5
Li, B., Zhang, J., Huang, A., Chen, Y., & Wei, Q. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132305 · Cited by 7
Chen, M., Little, P. J., Kong, S., Banach, M., Weng, J., & Xu, S. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.10.008 · Cited by 6
Molecular Targets and Small Molecules Modulating Acetyl Coenzyme A in Physiology and Diseases
Ewida, H. A., Benson, H., Tareq, S., & Ahmed, M. S. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00476 · Cited by 5
Therapies in autosomal dominant polycystic kidney disease: beyond tolvaptan
Fang, C., Norouzi, S., & Garimella, P. S. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001101 · Cited by 6
Korkmaz, A., Ünsal, V., Yıldız, R., Öner, E., & Atasoy, A. F. (2025) · Scientific Reports · doi:10.1038/s41598-025-18144-1 · Cited by 5
Fakas, S., & Odunsi, A. (2025) · Lipidology · doi:10.3390/lipidology2040020 · Cited by 5
“ACLY inhibition also upregulates low-density lipoprotein (LDL) receptors and attenuates atherosclerosis [29].”
Molecular targets of bempedoic acid and related decoy fatty acids
Supplee, J., Marmorstein, R., & Wellen, K. E. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.04.002 · Cited by 7
Diagnostik und Therapie von statinassoziierten Muskelsymptomen
Kassner, U., Grunwald, S. A., Spira, D., Buchmann, N., Bobbert, T., Gazzerro, E., Hollstein, T., Spuler, S., & Steinhagen‐Thiessen, E. (2021) · Der Internist · doi:10.1007/s00108-021-01059-0 · Cited by 5
Bempedoic Acid: A New Tool for LDL-Cholesterol Control in Patients with Coronary Artery Disease
Bilato, C., Sesti, G., & Averna, M. R. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2305156 · Cited by 6
“Because ACSVL1 is expressed in the hepatocytes but not in adipose tissue, intestine, or skeletal muscle [6], BA should cause considerably less muscle-related adverse effects compared to statin therapy [7].”
BackgroundDiscovery of Novel Long‐Chain Alkenyl Diacid Derivatives as ACLY Inhibitors
Song, G., Cao, L., Zhang, M., Yang, Y., Ma, J., Xie, Z., Li, J., & Nan, F. (2022) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202200362 · Cited by 5
Update on management of paediatric dyslipidaemia
Bansal, N., Kumar, S., & Brar, P. C. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000794 · Cited by 4
Ju, Z., Guan, X., Zhang, B., Wang, J., Jin, X., Zhao, Y., & Li, B. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00606-4 · Cited by 4
“In contrast to statins, bempedoic acid is a prodrug that undergoes activation in the presence of very-long-chain acyl-CoA synthetase 1 (ASCVL1), and the activated active substance acts upstream of HMG-CoA reductase [16–18].”
BackgroundBempedoic acid: a new player for statin-intolerant patients and beyond
Giordano, S. A., Spaccarotella, C., Esposito, G., & Indolfi, C. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000853 · Cited by 5
Ramachandran, S., Maarouf, A., Mitchell, K., Avades, T., Smith, P., Boulton, L., Kelly, J., Vekaria, N., & Hughes, E. (2024) · Drugs in Context · doi:10.7573/dic.2024-2-4 · Cited by 5
“2,9 Although bempedoic acid, much like statins, reduces cholesterol synthesis, it is not converted to its active form within skeletal muscle and therefore could be a beneficial treatment for patients who might otherwise be unable to tolerate the recommended dose of a statin.”
BackgroundAn update on trials of novel lipid-lowering drugs
Wierzbicki, A. S., Reynolds, T., & Viljoen, A. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000518 · Cited by 5
Major Concepts in Treatment with Bempedoic Acid and Inclisiran that Clinicians Need To Know
Parham, J. S., & Goldberg, A. C. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01036-4 · Cited by 6
Song, Z., Han, Q., Wen, Z., Lv, Q., Pan, C., & Pan, Y. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-6457 · Cited by 5
“Recent studies have demonstrated (20,21).”
Empleo del ácido bempedoico en los pacientes con dislipemia. Una aproximación práctica
Escobar, C., Barrios, V., Ariza, A., Campuzano, R., Martínez, J. M. G., & Mostaza, J. M. (2021) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(21)00005-4 · Cited by 7
Quantitative Sub-Cellular Acyl-Coa Analysis Reveals Distinct Nuclear RegulationPreprint
Trefely, S., Huber, K., Liu, J., Noji, M., Stransky, S., Singh, J. P., Doan, M. T., Lovell, C. D., von Krusenstiern, E. V., Jiang, H., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3885983 · Cited by 5
Cicero, A., Mahjoubin-Tehran, M., Reiner, Ž., Eid, A. H., Jamialahmadi, T., & Sahebkar, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100110 · Cited by 3
Tang, X., Mao, C.-R., Fang, J., Ma, Z., Huang, Y., & Wang, D. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202300538 · Cited by 4
Yang, Y., Zhai, J., Wang, F., Song, G., Xu, H., Sun, X., Zhang, Q., Ma, J., Gu, M., Gao, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00480 · Cited by 4
Metadata
- Authors
- Pinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., Steinberg, G. R., & Lalwani, N. D.
- Affiliations
- Esperion Therapeutics (United States) (US)
- McMaster University (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- Corresponding author
- Pinkosky, Stephen L.
- Steinberg, Gregory R.
- Venue
- Nature Communications
- Published
- 2016-11-28
- Volume
- 7
- Issue
- 1
- Pages
- 13457-13457
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5133702
- OpenAlex
- W2558991743
- Cited by
- 498
- References
- 73
- Citations by year
- 2026: 63 · 2025: 50 · 2024: 76 · 2023: 79 · 2022: 55 · 2021: 67 · 2020: 50 · 2019: 24 · 2018: 21 · 2017: 10 · 2016: 1
- FWCI
- 21.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- Amgen
- Heart and Stroke Foundation of Canada
- McMaster University
- Esperion Therapeutics
- Amgen Canada
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- bempedoic acid, ATP citrate lyase, LDL cholesterol lowering, atherosclerosis, prodrug activation, LDL receptor upregulation, AMPK, hypercholesterolemia, skeletal muscle
- MeSH terms
- Adenylate Kinase, Animals, ATP Citrate (pro-S)-Lyase, Dicarboxylic Acids, Enzyme Activation, Enzyme Inhibitors, Fatty Acids, Humans, Cholesterol, LDL, Liver, Mice, Inbred C57BL, Models, Biological, Organ Specificity, Receptors, LDL, Up-Regulation, Mice, Knockout, Disease Progression, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hepatocytes, Atherosclerosis, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.